Expert perspectives on the role of immunotherapies in upper gastrointestinal cancers, highlighting the CheckMate 649 study investigating frontline nivolumab plus chemotherapy.
Case: A 60-Year-Old Man with Stage IV Gastric Adenocarcinoma
Clinical Presentation:
Initial Clinical Workup and Diagnosis:
Current Treatments:
This is a video synopsis/summary of a Case-Based Peer Perspectives series featuring David Zhen, MD.
CheckMate649 led to the approval of nivolumab in combination with FOLFOX (leucovorin, fluorouracil [5-FU], and oxaliplatin) or CAPOX (capecitabine and oxaliplatin) for metastatic gastric cancer. The trial's primary end point focused on patients with a PD-L1 combined positive score (CPS) 5% of greater. Three-year follow-up data presented at the American Society of Clinical Oncology Annual Meeting demonstrated an overall survival benefit with a median of 14.4 months in the chemo-immunotherapy arm vs 11.1 months with chemotherapy alone (HR, 0.7). Progression-free survival and objective response rates also improved with the addition of immunotherapy.
KEYNOTE-859 led to the approval of pembrolizumab in this setting, despite the earlier negative KEYNOTE-062 study, which was underpowered. While the benefit of immunotherapy is clear for patients with PD-L1 CPS of 5% or above, the role of PD-L1 expression in guiding treatment decisions remains challenging. Some benefit may exist for patients with CPS of 1% or above, but the benefit is lacking for those with a CPS of 1% or below. Zhen continues to administer immunotherapy in his practice, given the overall patient population survival benefit, but he acknowledges the need to identify patients who are more likely to benefit while considering potential immune-related toxicities.
In practice, after 4 to 6 months of first-line chemo-immunotherapy without progression, Zhen often transitions to a maintenance regimen of 5-FU and nivolumab until disease progression, which has resulted in prolonged disease control for some patients.
Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.
PD-L1 Provides Valid Biomarker for Nivolumab/Chemo in Gastric Cancer
February 28th 2024In a discussion with Targeted Oncology, Michael Gibson, MD, PhD, discusses the benefits of using a patient’s PD-L1 combined positive score to determine if they are given nivolumab and chemotherapy to treat their gastric cancer.
Read More
Optimal Results: Neoadjuvant Durvalumab and Chemotherapy Drive Improvement in Gastric/GEJ Cancers
January 19th 2024The combination of neoadjuvant FLOT with durvalumab demonstrated enhanced pathological complete response compared to sole chemotherapy in individuals with resectable gastric and GEJ cancers, regardless of geographical location.
Read More
FDA Issues Complete Response Letter to Zolbetuximab BLA in GI Cancer
January 9th 2024The FDA has issued a complete response letter to the biologics license application of zolbetuximab for patients with advanced, HER2-negative, claudin 18.2-positive gastric or gastoesophageal junction adenocarcinoma.
Read More
FDA Approves Pembrolizumab/Chemo for Gastric and GEJ Adenocarcinoma
November 16th 2023Pembrolizumab and fluoropyrimidine- and platinum-containing chemotherapy are now FDA-approved for the treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Read More